Efficacy and Safety of Long-acting Injectable Cabotegravir and Rilpivirine in Improving HIV-1 Control in sub-Saharan Africa: Protocol for a Phase 3b Open-Label Randomized Controlled Trial (IMPALA).

Wellcome Open Res · 2025 · PMC12485332 · PMID 41040645

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Version 1 recommendation approve This is a highly significant randomized controlled trial investigating CAB+RPV in individuals with sub-optimal adherence, particularly in a resource-limited setting and among PWH with viremia.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.